Bernard Coulie (file photo)

With one ri­val down, No­var­tis-part­nered biotech scores $100M round to fund mid-stage tri­als of fi­bro­sis drug

When Pli­ant Ther­a­peu­tics bagged its $62 mil­lion B round al­most two years ago, CEO Bernard Coulie po­si­tioned its lead pro­gram in id­io­path­ic pul­monary fi­bro­sis right be­hind Bio­gen, which he sees as a fron­trun­ner 18 months ahead.

Com­ing in­to the Se­ries C, that’s no longer the case. Bio­gen scrapped its Phase II tri­al last Sep­tem­ber due to safe­ty con­cerns, leav­ing Pli­ant even more room to make a splash with the mid-stage pro­grams it now plans to run with $100 mil­lion of new cash in the bank.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.